Tags

Type your tag names separated by a space and hit enter

The Promise of a Malaria Vaccine-Are We Closer?
Annu Rev Microbiol. 2018 09 08; 72:273-292.AR

Abstract

Malaria vaccine development has rapidly advanced in the past decade. The very first phase 3 clinical trial of the RTS,S vaccine was completed with over 15,000 African infants and children, and pilot implementation studies are underway. Next-generation candidate vaccines using novel antigens, platforms, or approaches targeting different and/or multiple stages of the Plasmodium life cycle are being tested. Many candidates, in various stages of development, promise enhanced efficacy of long duration and broad protection against genetically diverse malaria strains, with a few studies under way in target populations in endemic areas. Malaria vaccines together with other interventions promise interruption and eventual elimination of malaria in endemic areas.

Authors+Show Affiliations

Department of Pediatrics, University of Maryland School of Medicine, Baltimore 21201, Maryland, USA; email: mlaurens@som.umaryland.edu. Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. Malaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore 21201, Maryland, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30200856

Citation

Laurens, Matthew B.. "The Promise of a Malaria Vaccine-Are We Closer?" Annual Review of Microbiology, vol. 72, 2018, pp. 273-292.
Laurens MB. The Promise of a Malaria Vaccine-Are We Closer? Annu Rev Microbiol. 2018;72:273-292.
Laurens, M. B. (2018). The Promise of a Malaria Vaccine-Are We Closer? Annual Review of Microbiology, 72, 273-292. https://doi.org/10.1146/annurev-micro-090817-062427
Laurens MB. The Promise of a Malaria Vaccine-Are We Closer. Annu Rev Microbiol. 2018 09 8;72:273-292. PubMed PMID: 30200856.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Promise of a Malaria Vaccine-Are We Closer? A1 - Laurens,Matthew B, PY - 2018/9/12/entrez PY - 2018/9/12/pubmed PY - 2019/8/28/medline KW - Plasmodium KW - adjuvants KW - elimination KW - malaria KW - vaccine delivery systems KW - vaccines SP - 273 EP - 292 JF - Annual review of microbiology JO - Annu Rev Microbiol VL - 72 N2 - Malaria vaccine development has rapidly advanced in the past decade. The very first phase 3 clinical trial of the RTS,S vaccine was completed with over 15,000 African infants and children, and pilot implementation studies are underway. Next-generation candidate vaccines using novel antigens, platforms, or approaches targeting different and/or multiple stages of the Plasmodium life cycle are being tested. Many candidates, in various stages of development, promise enhanced efficacy of long duration and broad protection against genetically diverse malaria strains, with a few studies under way in target populations in endemic areas. Malaria vaccines together with other interventions promise interruption and eventual elimination of malaria in endemic areas. SN - 1545-3251 UR - https://www.unboundmedicine.com/medline/citation/30200856/The_Promise_of_a_Malaria_Vaccine_Are_We_Closer L2 - https://arjournals.annualreviews.org/doi/10.1146/annurev-micro-090817-062427?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -